Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 4/20 | 0.38 |
| ▸ | CA2 | P00918 | 4/20 | 0.38 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2409484 | 0.87 | CA1 (0.47) | BTKCA1CA2CA12CA9 | |
| SCHEMBL2409582 | 0.83 | CA1 (0.42) | BTKCA1CA2CA12CA9 | |
| SCHEMBL12655356 | 0.83 | SLC40A1 (0.46) | BTKCA1CA2PDE3A | |
| SCHEMBL1134560 | 0.83 | CA1 (0.47) | CA1CA2CA12CA9 | |
| SCHEMBL1825015 | 0.82 | PDE4A (0.43) | CA1CA2CA12CA9PDE3A | |
| SCHEMBL1826005 | 0.81 | BTK (0.37) | LMNABTKCA1CA2CA12 | |
| SCHEMBL12319412 | 0.81 | CA1 (0.39) | BTKCA1CA2CA12CA9 | |
| SCHEMBL1824894 | 0.80 | CA1 (0.42) | LMNABTKCA1CA2CA12 | |
| SCHEMBL2405774 | 0.80 | PDE4A (0.52) | CA1CA2HSD17B2PDE4APDE4B | |
| SCHEMBL1822801 | 0.80 | CA2 (0.54) | LMNACA1CA2CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| WO-2011060199-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
| WO-2011060199-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2011-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212918-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | LMNA 3490/4885PIK3CD 3460/4885BTK 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.